Phaseline

Targets › S1PR3

S1PR3 (Sphingosine 1-phosphate receptor 3): drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 4, 1 Phase 3, 1 Phase 2; Neurology, Metabolic and endocrine, Oncology; next expected readout Sep 2027.

Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. (UniProt, Q99500)

Open in Phaseline: the race on S1PR3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisFingolimod
Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent
S1PR5, S1PR2, S1PR4, S1PR3, S1PR1Phase 4Multiple Sclerosis; Diabetes Mellitus, Type 2; Non Small Cell Lung CancerSep 2027

Conditions

Multiple Sclerosis (2) Diabetes Mellitus, Type 2 (1) Non Small Cell Lung Cancer (1)

Modalities

small molecule (1)

Companies

Novartis (1)

Related targets

S1PR5 (1) S1PR2 (1) S1PR4 (1) S1PR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.